144701-48-4 |
| 时间：2023-07-15 来源：化工号 作者：C33H30N4O2 |
| 中文名 | 替米沙坦
| | 英文名 | Telmisartan
| | 别名 | 替米沙坦
替米沙坦(标准品)
替米沙坦溶液, 100PPM
4'-[[2-丙基-4-甲基-6(1-甲基苯并咪唑-2-基)-苯并咪唑-1-基]甲基]-2-联苯羧酸
4-{[2-正丙基-4-甲基-6-(1-甲基苯并咪唑-2-基)苯并咪唑-1-基]甲基}联苯基-2-羧酸
4′-[4-甲基-6-(1-甲基-1H-苯并咪唑-2-基)-2-丙基-1H-苯并咪唑-1-基甲基]联苯基-2-羧酸
4'-[(1,4'-二甲基-2'-丙基-[2,6'-联-1H-苯骈咪唑]-1'-基)甲基]-[1,1'-联苯]-2-羧酸
替米沙坦 4'-[(1,4'-二甲基-2'-丙基[2,6'-联-1氢-苯并咪唑]-1'-基)甲基]-[1,1'-联苯]-2-羧酸
| | 英文别名 | Telmisartan
4'-(1,7'-Dimethyl-2'-propyl-1H-
4-chloromethyl-5-methyl-1,3-dioxol-2-tone
4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
4'-[{1,4'-Dimethyl-2'-Propyl[2,6'-Bi-1H-Benzimiaszol]-1'yl}-Methyl}-1,1'-Biphenyl-2-Caroxylic Acid
4'[(1,4'-Dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid
4''-(1,7''-DIMETHYL-2''-PROPYL-1H-[2,5'']BIBENZOIMIDAZOLYL-3''-YLMETHYL)-BIPHENYL-2-CARBOXYLIC ACID
[1,1'-Biphenyl]-2-carboxylicacid,4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]
2-[4-[[4-methyl-6-(1-methylbenzoimidazol-2-yl)-2-propyl-benzoimidazol-1-yl]methyl]phenyl]benzoic acid
tert-butyl 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylate
4'-[[4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-2-biphenylcarboxylic acid
BIBR 277, 4μ[(1,4μ-Dimethyl-2μ-propyl[2,6μ-bi-1H-benzimidazol]-1μ-yl)methyl][1,1μ-biphenyl]-2-carboxylic acid
4'-[{1,4'-Dimethyl-2'-Propyl[2,6'-Bi-1H-Benzimiaszol]-1'yl}-Methyl}-1,1'-Biphenyl-2-Caroxylic Acid Dimethyl Ethyl Ester
Telmisartan,4′[(1,4′-Dimethyl-2′-propyl[2,6′-bi-1H-benzimidazol]-1′-yl)methyl][1,1′-biphenyl]-2-carboxylic acid, BIBR 277
| | CAS | 144701-48-4
| | EINECS | 620-494-7 | | 化学式 | C33H30N4O2
| | 分子量 | 514.62 | | InChI | InChI=1/C33H30N4O2/c1-7-12-33-39-34-24(2)21-27(35-38-30-15-10-11-16-31(30)40(35)6)22-32(34)41(33)23-25-17-19-26(20-18-25)28-13-8-9-14-29(28)36(42)43-37(3,4)5/h8-11,13-22H,7,12,23H2,1-6H3 | | InChIKey | RMMXLENWKUUMAY-UHFFFAOYSA-N | | 密度 | 1.16 | | 熔点 | 261-263°C | | 沸点 | 771.9±70.0 °C(Predicted) | | 闪点 | 425.798°C | | 水溶性 | insoluble | | 蒸汽压 | 0mmHg at 25°C | | 溶解度 | DMSO: >5mg/mL at60°C | | 折射率 | 1.624 | | 酸度系数 | 3.86±0.36(Predicted) | | 存储条件 | 2-8°C | | 稳定性 | Hygroscopic | | 外观 | solid | | 颜色 | white | | Merck | 14,9129 | | 物化性质 | 白色结晶性粉末。 | | 产品用途 | 抗高血压药，血管扩张素拮抗药 | | MDL号 | MFCD00918125 | | 危险品标志 | Xi - 刺激性物品
| | 风险术语 | 36/37/38 - 刺激眼睛、呼吸系统和皮肤。
| | 安全术语 | S22 - 切勿吸入粉尘。
S24/25 - 避免与皮肤和眼睛接触。
S36 - 穿戴适当的防护服。
S26 - 不慎与眼睛接触后，请立即用大量清水冲洗并征求医生意见。
| | WGK Germany | 2 | | RTECS | DV2037500 | | 海关编号 | 2933995300 | | 上游原料 | N-甲基邻苯二胺盐酸盐 4'-溴甲基联苯-2-羧基叔丁酯 3,4,5-三氟苯甲酸甲酯 | | 参考资料 展开查看 | 1. [IF=3.365] Cailian Fei et al."LC-MS/MS method for quantifying aescinate A and B and assessing their relationship with phlebitis."Anal Biochem. 2022 Mar;:114636 |
|
|
|
|
